Morgan Stanley’s Foamix Pharmaceuticals FOMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
– Sell
-1,407,948
Closed -$4.69M – 6878
2019
Q4
$4.69M Buy
1,407,948
+1,406,396
+90,618% +$4.47M ﹤0.01% 3267
2019
Q3
$5K Hold
1,552
– – ﹤0.01% 6381
2019
Q2
$4K Sell
1,552
-43,692
-97% -$131K ﹤0.01% 6381
2019
Q1
$169K Buy
45,244
+17,037
+60% +$63.8K ﹤0.01% 5149
2018
Q4
$101K Buy
28,207
+23,207
+464% +$101K ﹤0.01% 5558
2018
Q3
$29K Sell
5,000
-49,580
-91% -$284K ﹤0.01% 6035
2018
Q2
$274K Buy
54,580
+26,203
+92% +$135K ﹤0.01% 5412
2018
Q1
$145K Buy
+28,377
New +$171K ﹤0.01% 5599
2017
Q3
– Sell
-20
Closed – – 6672
2017
Q2
$0 Hold
20
– – ﹤0.01% 6703
2017
Q1
$0 Buy
+20
New +$192 ﹤0.01% 6657
2016
Q4
– Sell
-832
Closed -$8K – 6606
2016
Q3
$8K Sell
832
-14,565
-95% -$122K ﹤0.01% 6162
2016
Q2
$98K Buy
15,397
+8,147
+112% +$54.1K ﹤0.01% 5253
2016
Q1
$47K Sell
7,250
-14,606
-67% -$94.2K ﹤0.01% 5635
2015
Q4
$177K Sell
21,856
-375
-2% -$2.8K ﹤0.01% 5150
2015
Q3
$163K Buy
22,231
+3,069
+16% +$31.3K ﹤0.01% 5189
2015
Q2
$196K Buy
19,162
+4,243
+28% +$46.9K ﹤0.01% 5249
2015
Q1
$139K Sell
14,919
-920
-6% -$8.23K ﹤0.01% 5391
2014
Q4
$111K Buy
15,839
+15,403
+3,533% +$88.1K ﹤0.01% 5505
2014
Q3
$2K Buy
+436
New +$2.5K ﹤0.01% 6458

Morgan Stanley's FOMX Position: Q1 2020 in Review

Morgan Stanley sold out of Foamix Pharmaceuticals (FOMX) in Q1 2020, closing a stake of 1,407,948 shares — an estimated $4.69M sold.

Morgan Stanley first reported a position in FOMX in Q3 2014 and held it in 19 quarters. The position peaked at $4.69M in Q4 2019. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.

  • Morgan Stanley reported no remaining Foamix Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Morgan Stanley sold 1,407,948 Foamix Pharmaceuticals shares in Q1 2020, an estimated $4.69M.
  • Morgan Stanley first reported a position in Foamix Pharmaceuticals in Q3 2014 and held it in 19 quarters.
  • Morgan Stanley's Foamix Pharmaceuticals position peaked at $4.69M in Q4 2019.
  • 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals as of Q1 2020.

Based on Morgan Stanley's 13F filing for Q1 2020, filed 15 May 2020.